Compare Alliant Energy Corporation (LNT) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alliant Energy Corporation vs Moderna, Inc. — how do they compare? Alliant Energy Corporation trades at $69.81 (market cap $17.78B), while Moderna, Inc. trades at $63.55 (market cap $24.18B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Alliant Energy Corporation pays a 3.12% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| LNT | MRNA | |
|---|---|---|
Market Cap | $17.78B | $24.18B |
Sector | Utilities | Health |
52-Week High | $78.03 | $81.80 |
52-Week Low | $63.62 | $22.36 |
Enterprise Value | $29.88B | $20.33B |
Dividend Yield | 3.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alliant Energy (LNT) trades at $68.21, down 1.67% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $0.65, beating estimates, and reaffirmed full-year guidance. Revenue grew to $4.36B in 2025, with net income margin at 18.45%. Analyst consensus is a Buy with a $77.67 price target, indicating potential upside. Recent news highlights institutional activity, including Assenagon Asset Management increasing its stake by 339.9% as of August 12, 2026.
LNT presents a stable investment opportunity with consistent earnings beats and a dividend yield, but faces risks from rising debt levels and bearish technical trends. The stock's valuation metrics, including a P/E of 21.7, are reasonable for the utilities sector. Upside is supported by analyst targets, while headwinds include higher interest costs and competitive pressures.
Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.
The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
